7. Cell therapy for liver regeneration

Riazuddin, Sheikh; Baig, Maria Tayyab; Mehmood, Azra

doi:10.1515/9783110587043-007

Cited by 2 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…During the past eight months, several reports have been published (16)(17)(18)(19) that suggest, MSCs, may prevent the cytokine storm and thus reduce the COVID-19 related morbidity. These reports, taken together (16)(17)(18)(19) with our previous successes (20)(21) with stem cell therapy in animal models has persuaded us to explore the MSC-based therapy for the treatment of COVID-19 patients. Here, we propose to evaluate the therapeutic e cacy of intravenous infusions of UC-derived MSCs in the treatment of COVID-19.…”

Section: Introductionmentioning

confidence: 93%

Efficacy of intravenous infusions of UC-derived MSCs for the treatment of COVID-19: A structured summary of a phase II double blinded, randomized controlled clinical trial

Ali

Mehmood

Tarar

et al. 2020

Preprint

Self Cite

View full text Add to dashboard Cite

In this clinical research project, we will conduct a highly rigorous clinical trial where we randomize the patients between umbilical cord (UC)-derived mesenchymal stem cell (MSC) and standard of care (SOC). This study will ask the question whether the allogenic MSCs are effective in reducing death and/or progression of COVID-19 disease when administered to patients with moderate to severe symptoms. MSCs are unique group of cells with minimal immune reactivity and produce multiple beneficial effects, which include reduction of severe inflammatory reaction. There is convincing evidence from human studies that intravenous (IV) delivery of MSCs can directly impact the hyper-inflammatory responses of COVID-19 induced injury of the heart and lungs. Our study will evaluate the safety and efficacy of allogenic UC-derived MSCs administered intravenously to COVID-19 patients with moderate to severe symptom in a randomized, controlled clinical trial. In addition, we will determine whether : (i) UC-derived MSCs are effective in reducing 30-day all-cause mortality (primary endpoint) and (ii) UC-derived MSCs are effective in preventing progression to mechanical ventilation, and/or reducing an inflammatory response, and/or improving overall patient condition (secondary endpoints).

show abstract

Section: Introductionmentioning

confidence: 93%

Efficacy of intravenous infusions of UC-derived MSCs for the treatment of COVID-19: A structured summary of a phase II double blinded, randomized controlled clinical trial

Ali

Mehmood

Tarar

et al. 2020

Preprint

Self Cite

View full text Add to dashboard Cite

show abstract

“…During the past eight months, several reports have been published (16)(17)(18)(19) that suggest, MSCs, may prevent the cytokine storm and thus reduce the COVID-19 related morbidity. These reports, taken together (16)(17)(18)(19) with our previous successes (20)(21) with stem cell therapy in animal models has persuaded us to explore the MSC-based therapy for the treatment of COVID-19 patients. Here, we propose to evaluate the therapeutic efficacy of intravenous infusions of UC-derived MSCs in the treatment of COVID-19.…”

Section: Introductionmentioning

confidence: 94%